Drug Search Results
More Filters [+]

NKTT-120

Alternative Names: nktt-120, nktt120, nktt 120
Latest Update: 2015-06-26
Latest Update Note: Clinical Trial Update

Product Description

NKTT120 is an anti-iNKT cell monoclonal antibody that has the potential to rapidly and specifically deplete iNKT cells and, potentially, prevent vaso-occlusion.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28152086/)

Mechanisms of Action: NKT Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: NKT
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NKTT-120

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Anemia, Sickle Cell

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

120-SCD1

P1

Completed

Anemia, Sickle Cell

2015-05-01

Recent News Events

Date

Type

Title